Drug intelligence / Profile preview

OC-884

Development stage: Preclinical
Lead developer: OncoCube Therapeutics
Modality: Small Molecules

Overview

OC-884 is a preclinical-stage small molecule therapeutic being developed by OncoCube Therapeutics for the treatment of solid tumors. As of late 2025, the program is in the lead optimization phase of development. While the specific molecular target remains undisclosed by the sponsor, the asset is part of OncoCube's internal oncology pipeline. It is distinct from the company's other programs, such as AO-252 (a TACC3 inhibitor licensed to A2A Pharmaceuticals).

Other names: OC-884OC884OC 884

Targets

TACC3 (Transforming acidic coiled-coil-containing protein 3)

Beyond the preview

Go deeper on OC-884.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-884.

Explore the full profile